The efficacy of continuous oral cytarabine ocfosfate (YNK01)(300 mg/day) in combination
with interferon alpha (IFNα, 5× 106 IU/day) was evaluated in patients with advanced chronic …

Recombinant® interferon α (r‐IFN‐α) has been shown to be an effective drug for chronic
myeloid leukaemia (CML). However, higher response rates can be achieved using …

Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to
systemic deamination after oral administration. Following initial studies indicating significant …

Background Treatment with interferon and subcutaneous cytarabine produces superior
cytogenetic responses in chronic myeloid leukaemia (CML) than treatment with interferon …

BACKGROUND AND OBJECTIVES: Subcutaneous Ara-C plus interferon (IFN) produces
more cytogenetic responses than IFN in chronic myeloid leukemia (CML) but a greater …

YNK01 (Starasid) is a prodrug that is adsorbed in the gut and is transformed in the liver in
arabinosyl cytosine (AC). Low-dose AC (LDAC) is useful for the treatment of Philadelphia …

This multicenter randomized phase III study was designed to compare the efficacy and
toxicity of IFNα-2c (3.5 MU/d) in combination with either araC (10mg/m2 d1-10) or …

Interferon-α (IFN-α) has significantly prolonged survival in chronic myeloid leukemia (CML),
but some patients do not respond and many responses are not durable. To improve the …

Newly diagnosed chronic myelogenous leukaemia (CML) patients (n= 65) were treated with
interferon (IFN)‐α2b (5× 106 IU/d sc) combined with monthly courses of cytarabine (20 mg/d …

Eleven previously untreated patients with chronic‐phase Philadelphia‐chromosome‐
positive chronic myelogenous leukemia were treated with cytotoxic chemotherapy followed …